Tango Therapeutics (TNGX) · vopimetostat + RAS(ON) inhibitors
Narrower window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: 2H 2026
Present 2/3L PDAC vopimetostat + RAS(ON) inhibitors combination data at a scientific conference 2H 2026
EX-99.1 · filed · SEC filing
After
Stated timing: October 23-27, 2026
We plan to share data from the Phase 1/2 trial of the combination of vopimetostat plus RAS(ON) inhibitors at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain from October 23-27, 2026.
SEC original · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/TNGX-vopimetostat-ras-on-inhibitors-2026-08-11, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/TNGX-vopimetostat-ras-on-inhibitors-2026-08-11
Tango Therapeutics (TNGX) pipeline and stated timing · Calendar · Companies A–Z